CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 37 enrolled
Drug / intervention
Leuprolide acetate in depot suspension +1 moredrug
Likely dose
Leuprolide acetate in depot suspension 3.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00621179
NCT00621179Phase 4Completed

Do Endometrial Implantation Markers Predict in Vitro Fertilization-embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension?

Colorado Center for Reproductive Medicine·interventional·Posted Feb 22, 2008·Updated Aug 10, 2021

In Brief

A Phase 4 clinical trial evaluating Leuprolide acetate in depot suspension and No intervention for Endometriosis and Infertility. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This prospective randomized trial evaluates whether one can predict which infertile women with endometriosis who are candidates for in vitro fertilization will benefit from prolonged therapy with a GnRH agonist by the determination of the absence of endometrial expression of the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for in vitro fertilization and then undergo randomization to a three month course of a depot preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian stimulation or standard therapy. prio

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 22, 2008
Enrollment StartMar 1, 2003
Primary CompletionAug 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 18.4 years ago

Interventions

Leuprolide acetate in depot suspensiondrug

Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3

No interventionother